公开(公告)号：EP1406997A2

公开(公告)日：2004-04-14

申请号：EP02741981.1

申请日：2002-06-07

申请人： Aventis Pharmaceuticals Inc.

发明人： WASEL-NIELEN, Monika ,  KIRSCHBAUM, Bernhard ,  FOSTER, Martyn ,  POLITES, Gregory ,  KHORKOVA, Olga ,  ZHU, Bin

IPC分类号： C12N1/00

CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03

摘要： Provided herein is a mouse that is unable to express functional alpha-4-integrin protein, and methods for assaying agents for alpha-4 integrin antagonist activity, as well as genetic markers for analyzing the efficacy of VLA-4 modulators, and particularly antagonists.

公开(公告)号：EP1737440A2

公开(公告)日：2007-01-03

申请号：EP05729215.3

申请日：2005-03-29

申请人： Aventis Pharmaceuticals, Inc.

发明人： CHANDROSS, Karen ,  MERRILL, Jean ,  MINNICH, Anne ,  LEE, Lan ,  KHORKOVA, Olga ,  LIU, Yun

IPC分类号： A61K31/192 ,  A61K31/426 ,  A61P25/02 ,  A61P25/28

CPC分类号： A61K31/426 ,  A61K31/192 ,  A61K2300/00

摘要： A method for treating demyelinating diseases in a patient in need thereof by treatment with an effective amount of a PPAR delta agonist is disclosed. Demyelinating diseases that may be effectively treated by this method include but are not limited to multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, Guillian-Barre syndrome and disorders in which myelin forming glial cells are damaged including spinal cord injuries, neuropathies and nerve injury.

公开(公告)号：EP1697409A1

公开(公告)日：2006-09-06

申请号：EP04811392.2

申请日：2004-11-18

申请人： Aventis Pharmaceuticals, Inc.

发明人： MERRILL, Jean ,  YAO, Zhengbin ,  PETKO, Wayne ,  KHORKOVA, Olga ,  KEESLER, George ,  WANG, Min

IPC分类号： C07K14/47 ,  A61K38/17

CPC分类号： G01N33/5011 ,  A61K31/727 ,  A61K38/1709 ,  C12Q1/26 ,  G01N33/5017 ,  G01N33/5047

摘要： A novel neuroprotectant was identified by microarray analysis that is differentially expressed between the ventricular zone and the cortex of human adult and fetal brain. The secreted protein antagonizes Wnt action in Xenopus embryos. Methods are described for modulating free radical neurotoxicity by contacting cells with the protein, treating neuronal diseases associated with free radical-mediated cell death by administering the protein, determining neuroprotective genomic targets associated with select free radical toxicity pathways by screening with the protein and using the protein to identify other compounds that modulate the biological activity of the secreted protein and the cell machinery that reacts to the secreted protein.

公开(公告)号：EP1517695A2

公开(公告)日：2005-03-30

申请号：EP03742164.1

申请日：2003-06-24

申请人： Aventis Pharmaceuticals, Inc.

发明人： MERRILL, Jean ,  PU, Su-Fen ,  KHORKOVA, Olga ,  JI, Zhongqi ,  CAMACHO, Fernando ,  BUSCH, Steve ,  WANG, Min ,  CHEN, Ting ,  DINERSTEIN, Robert, J. ,  YAO, Zhengbin ,  CHEN, Yangde ,  ZHANG, Xin ,  CHANDROSS, Karen ,  LEE, Lan

IPC分类号： A61K38/00 ,  A61K39/395 ,  C12Q1/00 ,  C12Q1/70 ,  G01N33/53 ,  G01N33/567

CPC分类号： G01N33/5058 ,  C07K16/24 ,  C12N5/0622 ,  C12N2501/585 ,  G01N33/5029 ,  G01N33/5073 ,  G01N2333/51 ,  G01N2800/285

摘要： Osteopontin is a marker for oligodendrocyte precursor cells. Osteopontin also modulates oligodendrocyte differentiation and central nervous system myelination. Osteopontin induces migration of oligodendrocyte precursors.